Global Regenerative Medicines Market is expected to reach USD 48.90 billion by 2021 | Market Data Forecast

Global Regenerative Medicines Marketis expected to reach USD 48.90 billion by 2021 from USD 17.20 billion in 2016, growing at a CAGR of 23.24% during the forecast period 2016-2021. Regenerative medicines repair, replace or regenerate human cells, tissues, or organs affected due to injury, disease, aging processes, congenital defects, and damage due to trauma.

These medicines restore normal functions of cells & tissues. These medicines are available in different types such as genes, somatic cells, stem cells, and other types. Some of these medicines (such as stem cells) have the ability to proliferate, differentiate thereby restore the original structure of cells or tissues or organs. Regenerative medicines are used in varied range of degenerative disorders include cardiovascular, neurodegenerative diseases, dermatology, and orthopedic, among others. Majority of the researchers aim to focus on the development of innovative technologies to provide better regenerative medicines and effective healthcare treatment solutions to patients.

Browse market data tables and in-depth TOC of the Global regenerative medicines marketto 2021 @ http://www.marketdataforecast.com/market-reports/global-regenerative-medicines-market-272/

Rising demand for biologically derived materials for regenerative medicine, growing technological advancements (nanotechnology based tissue engineering), and high support from government to promote the tissue engineering for the development of advanced therapies are driving the growth of global regenerative medicines market. In addition, growing utilization of regenerative medicines in cancer research & drug discovery, increasing organ transplantations, and rising healthcare expenditure are further stimulating the growth of global regenerative medicines market. However, presence of stringent regulatory pathways for tissue engineered products & cell-based products, strict ethical regulations for the utilization of human tissue, certain post-implantation infections & complications, and high cost for the research & development of cell-based products (such as stem cells).

Free sample of the report is available @http://www.marketdataforecast.com/market-reports/global-regenerative-medicines-market-272/request-sample

Global regenerative medicines market is segmented based on product, therapy, and application. Based on product, the market is further sub-segmented as cell-based products and acellular products. Of these, cell-based products segment is estimated to account for larger share of the global regenerative medicines market by product in 2016. Further, Cell-based products segment is classified as autologous and allogeneic products. Based on therapy, the market is segmented as cell therapy, gene therapy, tissue engineering, and immunotherapy. Of these, cell therapy is estimated to command the highest share of the global regenerative medicines market by therapy in 2016.

Based on application, the market is segmented as orthopedic & musculoskeletal spine, dermatology, central nervous system, cardiovascular, oncology, diabetes, and other applications. Among these, orthopedic & musculoskeletal spine is estimated to command the largest share of the global regenerative medicines market by application in 2016.

Inquire before buying @http://www.marketdataforecast.com/market-reports/global-regenerative-medicines-market-272/inquire

On the basis of geographical region the global regenerative medicines market is segmented as North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa. North America is estimated to command the highest share of 31.3% of the global regenerative medicines market in 2016, whereas Asia-Pacific is estimated to grow at the highest CAGR of 28.90% during the forecast period 2016-2021.

The key players in global regenerative medicines market such as, Vertex Pharmaceuticals Incorporated (U.S.), Acelity L.P. Inc. (U.S.), Celgene Corporation (U.S.), StemCells, Inc. (U.S.), Organogenesis Inc. (U.S.), NuVasive, Inc. (U.S.), Vericel Corporation (Genzyme) (U.S.), Japan Tissue Engineering Co., Ltd. (Japan), Cytori Therapeutics Inc. (U.S.), Advantagene, Inc. (U.S.), and Mesoblast Ltd. (Australia).

Contact:
Abhishek Shukla
Sales Manager (International Business Development)
Market Data Forecast
Direct Line: +1-888-702-9626
Mobile: +91 998 555 0206
Mail:abhishek@marketdataforecast.com

Visit Market Data Forecast Blog @ http://www.marketdataforecast.com/blog/
View latest Press Releases of MDF @ http://www.marketdataforecast.com/press-releases

Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, we cater to the needs of both individual and corporate clients. Our analyst team comprises expert professionals in market research, who with their collective knowledge and skillset dedicatedly serve clients from various industries and regions.

502, Kakatiya's Empire, Jubilee Gardens, Hyderabad, Telangana, India.

This release was published on openPR.